A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis

Inclusion Criteria: * Chronic AD that has been present for ≥6 months * Validated-Investigator's Global Assessment score of ≥3 * EASI of ≥16 * BSA of AD involvement of ≥10% Exclusion Criteria: * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening * Use of certain medications * Presence of skin comorbidities or other condition(s) that may interfere with study assessments * Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry